MANE stock forecast, quote, news & analysis
Veradermics Inc clinical-stage biopharmaceutical company focused on developing therapeutics to address pervasive treatment challenges in prevalent aesthetic and dermatological conditions... Show more
Why Veradermics (MANE) Stock Is Up +21% in the Last 30 Days
Key Takeaways
- Veradermics (MANE) shares climbed roughly 21% over the 30 trading days through November 10, 2026, closing at $148.44.
- The advance was powered by positive late-stage clinical results for VDPHL01, the company's extended-release oral minoxidil candidate for pattern hair loss.
- Wall Street responded with higher price targets, and the stock now carries a consensus "Strong Buy" rating with an average target near $178.
- Third-quarter results reported a net loss of $21.0 million, though a $798.4 million cash position is expected to fund operations into 2030.
- Over the broader quarter, MANE gained roughly 36%, extending a rally that has lifted the shares several-fold since the company's February 2026 IPO.
- Veradermics remains pre-revenue, making regulatory and clinical milestones the primary drivers of the stock.
- For additional context on valuation and expectations, explore Price Targets, Earnings, and Forecast pages for this ticker.
- Investors seeking data-driven trading ideas can also explore Trending AI Robots.
Veradermics (MANE) Company Overview and Market Position
Veradermics, Incorporated is a dermatologist-founded, late clinical-stage biopharmaceutical company headquartered in New Haven, Connecticut. The company develops innovative therapeutics for highly prevalent aesthetic and dermatological conditions, with a primary focus on pattern hair loss, also known as androgenetic alopecia. Its lead program, VDPHL01, is a proprietary extended-release oral formulation of minoxidil, a proven hair-growth agent designed to deliver sustained absorption while minimizing the cardiac risks associated with immediate-release oral minoxidil.
If approved, VDPHL01 would represent the first FDA-approved oral, non-hormonal treatment for pattern hair loss in nearly three decades. The condition affects an estimated 80 million people in the United States, and the company has cited market estimates projecting the broader aesthetics segment at roughly $30 billion by 2028. Veradermics completed its initial public offering on the New York Stock Exchange in February 2026 at $17.00 per share and remains pre-commercial, with no approved products or meaningful revenue.
Veradermics (MANE) Stock Price Performance: Last 30 Days vs. Quarter
Over the 30 calendar days through November 10, 2026, MANE advanced from a closing price of $122.40 on October 12 to $148.44, a gain of approximately 21%. The move accelerated following the release of positive Phase 3 data and a series of upward analyst price-target revisions, pushing the shares to new highs.
The quarterly trend is even more pronounced. Measured from a closing price of $108.95 on August 11, the stock rose roughly 36% over the trailing three months. This multi-month advance reflects a steady re-rating of the shares as Veradermics transitioned from an early-stage story to a late-stage candidate with registration-directed data across multiple trials.
What Drove MANE Stock Price in the Last 30 Days
The dominant catalyst over the past month was clinical data. On October 19, Veradermics announced positive topline results from Phase 3 Study '304' in males with mild-to-moderate pattern hair loss. VDPHL01 met all primary and secondary endpoints, showing a mean target-area hair count increase of 36.4 hairs per square centimeter in the twice-daily arm and 28.6 in the once-daily arm at six months, compared with 6.6 for placebo. Patient-reported improvements in hair coverage also favored the treatment arms.
On November 9, the company reported positive 12-month long-term data from Part B of Phase 2/3 Study '302', showing deepening hair-count gains of 43.9 hairs per square centimeter in the twice-daily arm and maintained gains in the once-daily arm, with no new safety signals. These results reinforced the durability of the treatment effect and supported the case for regulatory submission.
Analyst activity followed. B. Riley raised its price target to $204 from $170, Citi raised its target to $175 from $160, and Leerink Partners raised its target to $150 from $135, each maintaining a buy-equivalent rating. On November 10, Veradermics reported third-quarter results showing a net loss of $21.0 million and a cash balance of $798.4 million, a runway management expects to fund operations into 2030.
What Drove MANE Stock Performance Over the Last Quarter
The quarterly rally reflects a broader narrative of accumulating clinical validation. Beginning in the summer, Veradermics reported positive Phase 2 data in female pattern hair loss, followed by analyst coverage initiations and a sustained uptrend. The October Phase 3 '304' readout marked the clearest inflection point, as it delivered the first registration-directed evidence that VDPHL01 could be both effective and well tolerated.
Sentiment was further supported by the stock's structure as a recently public, tightly focused developer addressing a large, underserved market with limited approved treatment options. The combination of positive data, rising price targets, and a well-capitalized balance sheet has driven a sustained re-rating, taking the shares well above their $17.00 IPO price.
Trending AI Robots
Tickeron offers hundreds of AI-powered trading bots that monitor and trade thousands of tickers, applying a range of strategies, timeframes, and performance metrics. Only the top-performing and most relevant bots are featured in the curated Trending AI Robots section, where traders can review recent activity, strategy details, and performance data. The bots vary in approach, from short-term momentum models to longer-horizon trend strategies, giving users a way to compare different automated approaches before deciding whether any align with their own objectives. Investors interested in exploring how algorithmic strategies are positioned across the market can browse the section to see which systems are currently gaining traction.
MANE Stock Forecast Drivers: What Investors Should Watch Next
Going forward, investors are likely to focus on Veradermics' regulatory pathway for VDPHL01, including the timing of a potential New Drug Application submission and the associated FDA review. Additional clinical catalysts include the Phase 2/3 Study '306' readout in female pattern hair loss and the completion of long-term safety data from the ongoing '302' program.
As a pre-revenue company, Veradermics' valuation depends heavily on continued clinical success and eventual commercialization. Risks include potential regulatory setbacks, clinical trial outcomes, competitive developments, and the costs of building a commercial organization. Macroeconomic conditions and broader biotech sector sentiment may also influence trading in the shares. Investors should monitor company announcements, analyst updates, and regulatory filings rather than relying on price action alone.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for MANE turns positive, indicating new upward trend
MANE saw its Momentum Indicator move above the 0 level on November 06, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 14 similar instances where the indicator turned positive. In 13 of the 14 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for MANE just turned positive on November 10, 2026. Looking at past instances where MANE's MACD turned positive, the stock continued to rise in 7 of 7 cases over the following month. The odds of a continued upward trend are 90%.
MANE moved above its 50-day moving average on October 19, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +6.96% 3-day Advance, the price is estimated to grow further. Considering data from situations where MANE advanced for three days, in 42 of 47 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
The Aroon Indicator entered an Uptrend today. In 26 of 28 cases where MANE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
Bearish Trend Analysis
The 10-day RSI Indicator for MANE moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 9 similar instances where the indicator moved out of overbought territory. In 7 of the 9 cases, the stock moved lower in the following days. This puts the odds of a move lower at 78%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MANE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.
MANE broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.127) is normal, around the industry mean (3.498). P/E Ratio (-55.597) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. MANE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 80 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MANE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
What does notional value mean?
What Part of the Contribution into My IRA is Tax-Deductible?
What Should I Do With a Lump-Sum Distribution From My Cash-Balance Plan?
How Do You Understand Tax Returns: Importance, Retention, and Deductions?
AI Bot Trading: Top 5 Day Traders, Virtual Accounts, on November 14, 2024
General Information
Industry Biotechnology